about
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociAdvanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: could the pathologist be further helped?Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseSystematic review: macrophage activation syndrome in inflammatory bowel diseaseDiagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and childrenEarly post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.Medical management of Crohn's disease.Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.Could JC virus provoke metastasis in colon cancer?Infliximab and ulcerative colitis.Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.Infliximab to treat Crohn's disease: an update.Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Burden of Crohn's disease: economics and quality of life aspects in Italy.Methodology for high-quality studies on course and prognosis of inflammatory bowel disease.Postoperative maintenance therapy for inflammatory bowel disease.Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.Clinical course of ulcerative colitis.Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.Is 5-ASA still the treatment of choice for ulcerative colitis?The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literatureHeart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases.Mesalazine for the treatment of inflammatory bowel disease.Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease.Comparing medical treatments for Crohn's disease.Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients.Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: an IG-IBD study.Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease.An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies.Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors.Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.Oral valganciclovir for colonic dilatation in ulcerative colitis associated with human cytomegalovirus infection.Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.Budesonide MMX and mesalamine to induce remission in patients with ulcerative colitis.Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.
P50
Q24618592-1780BC52-B267-47E4-B069-F95AF0AAD825Q26865465-5C5E3C58-5F1B-4520-B903-0183E0CDEA8CQ26866940-65A205AD-C2CA-4CA0-BC11-0D47E8A1CCB8Q27025349-67BCA3A1-B3CD-46BF-A002-319813920A5BQ28196268-E6399BBB-46E8-4CCA-9126-09F352276707Q30778152-A639075D-B411-45A4-BF76-D1A167B5D140Q34046139-9B08CCE3-D6D4-4E4C-90C0-E2313853C868Q34187731-047F78FB-1B81-462B-A0B3-5D2BF0C052DBQ34499114-BA5B164B-4976-4F62-95D7-A37074E90585Q34503548-76A978BD-9321-4D21-9707-8F2353746525Q34566470-AFC54119-A4DB-48FA-BD90-7B8CDC87F22CQ35304737-30D04B44-1B41-416B-881F-2A89F5D4A21DQ36127192-0F0B389A-F2E4-462E-A75F-2E8F57E7A102Q36136475-68460D13-FD1D-41FB-A353-49F5977BBA2CQ36144464-875213CB-580C-4657-9D43-D7F9B6C220EDQ36500015-699466F1-032C-4662-BC7D-7688E8FF5D02Q37111979-04295E7D-36F9-4CEA-BA25-1A4AD95D0D72Q37206543-F216DB8A-EB75-41F5-9B2F-85124609B685Q37281815-D655CB7C-BD5C-4F5E-B166-39E9814719A2Q37379002-84093D41-2AF0-41AD-B9A1-1AC608C7BA98Q37861853-0034449B-244A-42A6-9C90-23F4A32E8A29Q38055153-154825C4-C26E-4744-A047-51A7849C7C31Q38075303-A947A091-E5E2-461A-927E-2928C3E0C361Q38114476-59C17517-66A0-4658-849A-6EDDFA0E7DADQ38133080-64BEC41B-FEF5-4F8D-8120-24716DCC7D3AQ38162880-5CE6D764-F0EF-4DC1-93D5-175A42F0EEAEQ38194708-B3295337-0394-4F47-9508-AEE36098995DQ41340614-6CCAE719-F2A0-40C0-8A23-6FA54D7C10B1Q42788674-610EFB0E-08EB-4E0F-AED1-1B2B6AAC55BCQ42792213-6B5A7795-050C-4A73-BA59-8C74F0C15102Q43000002-04000B56-0A9D-4BF0-AC79-BB7AA68D8856Q43037130-581DE87B-9911-46F7-8057-816CF1EC4ABFQ43242162-80A03049-0645-4C6A-B88A-28D11FB09337Q43248947-73DE8199-1571-4E36-95D9-0722CC0100E4Q43284326-94A4C529-C4D2-4AFE-B5DA-2B93FCC00BCFQ43292530-2B6B4139-09A3-4B3C-8978-8D1B097BEFEBQ43560942-AFAF66AE-1991-4244-ABE5-5A39BBCA769BQ43771607-580934EB-8387-4FDF-852B-C5BC7A9A296DQ44019345-D613A85C-C725-41B0-AE6D-66BB90651C0CQ44290404-E8B3F251-934B-4A77-9DB0-8694762A43D8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Cottone
@ast
Mario Cottone
@en
Mario Cottone
@es
Mario Cottone
@nl
Mario Cottone
@sl
type
label
Mario Cottone
@ast
Mario Cottone
@en
Mario Cottone
@es
Mario Cottone
@nl
Mario Cottone
@sl
prefLabel
Mario Cottone
@ast
Mario Cottone
@en
Mario Cottone
@es
Mario Cottone
@nl
Mario Cottone
@sl
P106
P1153
12752119000
P21
P31
P496
0000-0003-1523-7556